Jay Dong – General Manager (China and APAC) & Vice President…
Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the…
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology, as well as musculoskeletal system, alimentary tract and metabolism, blood and blood-forming organ, genito-urinary system and sex hormone, and other therapeutic areas.
It provides approximately 800 varieties of drugs and 20 dosage forms. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it operates a network of retail pharmacy stores, as well as engages in consulting service, assets management, investment holding operations, etc. Further, the company manufactures and trades in medicines, and medical equipment and instruments; and rents properties, as well as wholesales chemicals and active pharmaceutical ingredients. It operates approximately 1,892 chained pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People’s Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the…
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to…
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of Cornerstone…
Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish…
Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine; his philosophy of putting patient needs at the…
China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal. The committee will not be limited to overseeing gene editing…
Yuichi Yomasu, president of Daiichi Sankyo China, shares his first impressions of the dynamic but complex Chinese market since he assumed position ten months ago; the strategic importance of the…
Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art…
Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic…
Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic…
While others have failed during the last 30 years, Hua Medicine has finally succeeded in developing a breakthrough diabetes treatment controlling blood glucose levels by taking a novel approach and…
Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List…
See our Cookie Privacy Policy Here
